Genioo’s Post

Optimized Molecules for Optimized Profiles: An AI-Driven Platform for Small Molecule Drug Discovery with Fred Manby from Iambic Therapeutics. Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need. Our platform enables us to widely explore chemical space, while also sampling a wide range of target product profiles. We have demonstrated our platform on initial programs, with our first scheduled for clinical entry just two years after launch. https://lnkd.in/eDBzUurr Save $150 with Discount code SPK150. #drugdiscoverychemistry

Discover the transformative journey of METiS Therapeutics with Techspert! By leveraging Techspert's cutting-edge solutions, METiS has significantly streamlined its drug discovery process, achieving: ⌛ A 70% reduction in research admin time 🚀 50%+ of expert profiles delivered within 24 hours ✅ An 80% acceptance rate for expert profiles With expert insights, METiS made strategic pivots, saving millions in development costs 💰 Ready to enhance your research efficiency and drive innovation? Read the complete case study to see the results we could bring to you: https://lnkd.in/e7gQkzgb

This isn't your typical drug sponsor + CDMO story. CTMC's Jason Bock says you shouldn't even classify his company as a CDMO. He's not wrong. On #BusinessOfBiotech, Thomas Leitch of KSQ Therapeutics, Inc. and Jason share their partnership story. "Our platform led us to some unique and very promising targets. But as as you alluded to earlier, Matt, having a target is not the same thing as having a therapy. And having a therapy is not the same thing as delivering a patient outcome. And our partnership with CTMC has really helped us accelerate those leads for targeted therapy to uninterrupted supply and and ultimately patient outcomes." Tom Leitch, CTO at KSQ Therapeutics. "And so, because we were running these studies already with MD Anderson - we've done many of these studies - we've got all of those logistics worked out. And so for our partners, they don't have to bother with any of it, we coordinate directly within the MD Anderson clinic. When they have a patient, we work out that we make sure we have a slot and we manufacture that product and then keep them informed and get that product back to the clinicians to infuse into the patients. And so, partners have full visibility into what's going on." Jason Bock, CEO, CTMC+. Thank you, Matthew Pillar and Bioprocess Online, for sitting down with Jason and Tom to hear the story of this exciting partnership. #biotech #celltherapy #TILtherapy #endcancer

If like Alexis Moreno and Reece Gardner you're working on challenging targets like GPCRs and IDPs, join this upcoming webinar where they'll share how they successfully measured binding affinities with Spectral Shift!

 Streamlining your workflow just got easier! Check out our latest infographic on "Optimizing Cell Line Development for Accelerated Therapeutics Production," proudly sponsored by Sartorius. 🧬 This resource offers practical tips and innovative solutions to enhance your production process, saving you time and boosting efficiency in the lab. 🕒✨ By applying these strategies, you're not just speeding up development; you're also ensuring higher quality outcomes. Don’t miss out—click to learn more and share with your network today! 🔗 Download Infographic Here: https://lnkd.in/exXkdHgp #CellLineDevelopment #TherapeuticsProduction #LabManagement

𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗟𝗮𝗯𝗜𝗡𝗔𝗥 𝗕𝗿𝗲𝗮𝗸 𝘆𝗲𝘁? Time is running out – this event is happening on Thursday! 📅 Date: May 16th, 2024 🕓 Time: 16:00 CEST Reserve your seat for an enlightening first session with Dr. Matthias Gossmann at the LabINAR BREAK, hosted by innoVitro. Discover the transformative strategies in drug discovery using iPSC-cellular models during the webinar “Transforming Drug Discovery: Accelerating Regulatory Acceptance by Integrating Throughput into Microphysiological Systems". What can you expect? ▪️ Case studies highlighting the successful application of these models ▪️ Insights on utilizing cell-based platforms for efficient preclinical drug screening ▪️ An engaging & interactive Q&A sessions with field experts. Will we see you at the webinar? Register today to reserve your spot. Secure your registration: https://ow.ly/JTE950RuB0I #InnovativeDrugDiscovery #Webinar #HighThroughput #iPSCModels #Preclinical #PharmaceuticalDevelopment

#News: Evotec announced further progress of the company’s strategic partnership with Bristol Myers Squibb relating to building a #molecularglue-based pipeline, triggering a $75 million performance-based and program-based milestone payment to #Evotec.   Initiated in 2018, the partnership combines Evotec’s high-performance #multiomics #screening and #analytics capabilities with #BristolMyersSquibb’s library of #cereblon #E3 #ligasemodulators (CELMoDs). Expanded in 2022, the partnership continues to identify #novelmoleculargluedegraders, targeting high-value targets in the field of #oncology and beyond.    Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “Bristol Myers Squibb is leading the industry in the field of molecular glue degraders, which is clearly one of the most exciting emerging therapeutic modalities. Through our highly systematic and industrialized PanOmics-based approach the pipeline of molecular degraders addressing high value targets keeps growing and maturing. The breadth and the depth of the pipeline is designed to deliver multiple first-in-class products into the market. We are well on track to deliver on our plans.” 🕮 Read more from Contract Pharma 👉🏼 https://lnkd.in/eWgevNNg

In the most recent Spring Edition of Drug Discovery World, our CEO, Nicholas Siciliano, shares insights on the curative potential of CAR-T therapeutics and how Vittoria is helping shape the future of immunotherapy. To check out the full piece, read here: https://shorturl.at/bcrtN

Agilent is hosting an Immunotherapy Symposium, followed by a “Live” Demo reception on March 26– in Cambridge from 1pm-6.30pm EST. Seats are limited— register today! Meet industry experts and explore solutions in real-time, impedance-based analysis of cell function, real time metabolism, cell imaging and microscopy, flow cytometers, and more! Learn about our Cell Analysis applications and workflows, get your Software questions answered, and learn how you can get personalized training on YOUR DATA! Heather Sampson Lustig Suzie Shoup Sabrina Hawthorne Jenny (Zhe) Zhang Craig Abrahams Natalia Romero Leyna Z. Diane Kambach, Ph.D. Suzanne Armitstead Melanie Herscovitch Cliff Leavitt Jason Field Daniel Disher Lauren Dostillio Peggy Taphorn Leena Paul, Ph.D #seahorse #immunology #cellandgenetherapy #flowcytometry #metabolism #metabolomics #celltherapymanufacturing #immunooncology #immunotherapy #microscopy #confocal #imaging

Check out Proactive's research note that delves into some of our key programmes, each targetting large addressable markets such as #oncology, #flu, #RSV, #obesity and more.   The piece also covers our recent collaboration with a Nasdaq listed biopharma💊 using our oral delivery technology.   Read it here ⬇️ https://lnkd.in/epAmzseE